Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study

INTRODUCTION: Several studies have shown increased incidence, recurrence, and severity of Clostridium difficile infection (CDI) over the last decade. Patients with inflammatory bowel disease (IBD) who develop CDI are more prone to morbidity and mortality than CDI in patients without IBD. This study...

Descripción completa

Detalles Bibliográficos
Autores principales: Saad Alshahrani, Abdulaziz, Mohammad, Danah, attieh Alzahrani, Mohammad, Narula, Neeraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448164/
https://www.ncbi.nlm.nih.gov/pubmed/37638216
http://dx.doi.org/10.1016/j.jsps.2023.101736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448164/
https://www.ncbi.nlm.nih.gov/pubmed/37638216
http://dx.doi.org/10.1016/j.jsps.2023.101736

Ejemplares similares